Skip to main content
Top
Published in: Immunologic Research 3/2018

01-06-2018 | Original Article

Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Centers Network on disease classification, regional trends, treatment modalities, and physician reported outcomes

Authors: Vicki Modell, Jordan S. Orange, Jessica Quinn, Fred Modell

Published in: Immunologic Research | Issue 3/2018

Login to get access

Abstract

Primary immunodeficiencies (PI) are genetic defects of the immune system that result in chronic, serious, and often life-threatening infections, if not diagnosed and treated. Many patients with PI are undiagnosed, underdiagnosed, or misdiagnosed. In fact, recent studies have shown that PI may be more common than previously estimated and that as many as 1% of the population may be affected with a PI when all types and varieties are considered. In order to raise awareness of PI with the overall goal of reducing associated morbidity and mortality, the Jeffrey Modell Foundation (JMF) established a network of specialized centers that could better identify, diagnose, treat, and follow patients with PI disorders. Over the past decade, the Jeffrey Modell Centers Network (JMCN) has provided the infrastructure to accept referrals, provide diagnosis, and offer treatments. Currently, the network consists of 792 Expert Physicians at 358 institutions, in 277 cities, and 86 countries spanning 6 continents. JMF developed an annual survey for physician experts within the JMCN, using the categories and gene defects identified by the International Union of Immunological Societies Expert Committee for the Classification of PI, to report on the number of patients identified with PI; treatment modalities, including immunoglobulins, transplantation, and gene therapy; and data on gender and age. Center Directors also provided physician-reported outcomes and differentials pre- and post-diagnosis. The current physician-reported data reflect an increase in diagnosed patients, as well as those receiving treatment. Suspected patients are being identified and referred so that they can receive early and appropriate diagnosis and treatment. The significant increase in patients identified with a PI is due, in part, to expanding education and awareness initiatives, newborn screening, and the expansion of molecular diagnosis and sequencing. To our knowledge, this is the most extensive single physician report on patients with PI around the world.
Literature
1.
go back to reference Modell V. The impact of physician education and public awareness on early diagnosis of primary immunodeficiencies. Immunol Res. 2007;38:43–7.CrossRefPubMed Modell V. The impact of physician education and public awareness on early diagnosis of primary immunodeficiencies. Immunol Res. 2007;38:43–7.CrossRefPubMed
2.
go back to reference Modell F. Immunology today and new discoveries: building upon legacies of Dr. Robert a. Good. Immunol Res. 2007;38:48–50.CrossRefPubMed Modell F. Immunology today and new discoveries: building upon legacies of Dr. Robert a. Good. Immunol Res. 2007;38:48–50.CrossRefPubMed
3.
go back to reference Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol. 2005;5:880–92.CrossRefPubMed Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol. 2005;5:880–92.CrossRefPubMed
4.
go back to reference Cooper MA, Pommering TL, Koranyi K. Primary immunodeficiencies. Am Fam Physician. 2003;68:2001–8.PubMed Cooper MA, Pommering TL, Koranyi K. Primary immunodeficiencies. Am Fam Physician. 2003;68:2001–8.PubMed
6.
go back to reference Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRefPubMed Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRefPubMed
7.
go back to reference Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.CrossRefPubMed Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.CrossRefPubMed
13.
go back to reference Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.CrossRefPubMed Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.CrossRefPubMed
14.
go back to reference Modell F, Puente D, Modell V. From genotype to phenotype. Further studies measuring the impact of a physician education and public awareness campaign on early diagnosis and management of primary immunodeficiencies. Immunol Res. 2009;44(1–3):132–49.CrossRefPubMed Modell F, Puente D, Modell V. From genotype to phenotype. Further studies measuring the impact of a physician education and public awareness campaign on early diagnosis and management of primary immunodeficiencies. Immunol Res. 2009;44(1–3):132–49.CrossRefPubMed
19.
go back to reference Bundorf KM, Royalty A, Baker LC. Health care cost growth among the privately insured. Health Aff. 2009;28(5):1294–304.CrossRef Bundorf KM, Royalty A, Baker LC. Health care cost growth among the privately insured. Health Aff. 2009;28(5):1294–304.CrossRef
20.
go back to reference Truven Health Analytics. Healthcare Spending Index for Employer-Sponsored Insurance. 2014. Truven Health Analytics. Healthcare Spending Index for Employer-Sponsored Insurance. 2014.
24.
go back to reference Fronstin P. Sources of health insurance and characteristics of the uninsured: analysis of the March 2013 current population survey, vol 390. EBRI (Employee Benefit Research Institute) Issue Brief No. 390, September 2013, Washington, DC; 2013. p. 1–36. Fronstin P. Sources of health insurance and characteristics of the uninsured: analysis of the March 2013 current population survey, vol 390. EBRI (Employee Benefit Research Institute) Issue Brief No. 390, September 2013, Washington, DC; 2013. p. 1–36.
25.
go back to reference Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab. 2011;104(3):383–9.CrossRefPubMedPubMedCentral Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab. 2011;104(3):383–9.CrossRefPubMedPubMedCentral
27.
go back to reference Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.CrossRefPubMed Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.CrossRefPubMed
31.
go back to reference Menzin J, Sussman M, Munsell M, Zbrozek A. Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy. Clinicoecon Outcomes Res. 2014;6:297–302.CrossRefPubMedPubMedCentral Menzin J, Sussman M, Munsell M, Zbrozek A. Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy. Clinicoecon Outcomes Res. 2014;6:297–302.CrossRefPubMedPubMedCentral
32.
go back to reference Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Immunology. 2013;13:635–48.PubMed Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Immunology. 2013;13:635–48.PubMed
34.
go back to reference Bharat ST, Alizadehfar R, Desrosiers M, Shuster J, Pant N, Tsoukasa CM. Adult primary immune deficiency: what are we missing? Am J Med. 2012;125(8):779–86.CrossRef Bharat ST, Alizadehfar R, Desrosiers M, Shuster J, Pant N, Tsoukasa CM. Adult primary immune deficiency: what are we missing? Am J Med. 2012;125(8):779–86.CrossRef
36.
go back to reference Keller MD, Bollard CM, Hanley PJ, McCormack S, Heimall J, Bunin N, et al. Viral-specific T lymphocytes for treatment of viral infections in primary immunodeficiency. Biol Blood Marrow Trans. 2015;21(2):S229–30.CrossRef Keller MD, Bollard CM, Hanley PJ, McCormack S, Heimall J, Bunin N, et al. Viral-specific T lymphocytes for treatment of viral infections in primary immunodeficiency. Biol Blood Marrow Trans. 2015;21(2):S229–30.CrossRef
Metadata
Title
Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Centers Network on disease classification, regional trends, treatment modalities, and physician reported outcomes
Authors
Vicki Modell
Jordan S. Orange
Jessica Quinn
Fred Modell
Publication date
01-06-2018
Publisher
Springer US
Published in
Immunologic Research / Issue 3/2018
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-018-8996-5

Other articles of this Issue 3/2018

Immunologic Research 3/2018 Go to the issue